Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
SAN DIEGO, Aug. 09, 2017 -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Officer, will present at the 2017 Wedbush PacGrow Healthcare Conference in New York on Wednesday, August 16, 2017 at 1:20 p.m. ET.
A live webcast of the presentation will be available through the investor relations section of the Company's website at www.fatetherapeutics.com. Following the live webcast, an archived replay will be available on the Company's website.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders. The Company's hematopoietic cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf product candidates derived from engineered pluripotent cell lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients undergoing hematopoietic cell transplantation and to promote immune tolerance in patients with autoimmune disease. Its adoptive cell therapy programs are based on the Company's novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact: Christina Tartaglia Stern Investor Relations, Inc. 212.362.1200 [email protected]
